Stocks of Cognition Therapeutics Inc (NASDAQ:CGTX) traded higher last session on Wall Street, down -18.91% to $0.57.
CGTX stock price is now 63.26% away from the 50-day moving average and 19.99% away from the 200-day moving average. The market capitalization of the company currently stands at $35.17M.
With the price target enhanced from $1 to $1.50, B. Riley Securities Upgraded its rating from Neutral to Buy for Cognition Therapeutics Inc (NASDAQ: CGTX). , while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, Ricciardi Lisa, CEO & President bought 38,851 shares of the company’s stock on Jan 31 ’25. The stock was bought for $30,001 at an average price of $0.77. Upon completion of the transaction, the CEO & President now directly owns 38,851 shares in the company, valued at $22145.07. A total of 19.35% of the company’s stock is owned by insiders.
During the past 12 months, Cognition Therapeutics Inc has had a low of $0.22 and a high of $2.54. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 2.09, and a quick ratio of 2.09.
The company reported revenue of $13.78 million for the quarter, compared to $14.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.32 percent.
